Jun Liao

Featured in: Favicon

nature.com Favicon

sciencedirect.com Favicon

biomedcentral.com (+1) Favicon

hindawi.com Favicon

optica.org Favicon

jbc.org + 3 more

Articles

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials - Nature Medicine

2 weeks ago | nature.com | Ying Cheng |Jun Liao |Jordi Rodon |Yongsheng Li |Yun Fan |Jin Billy Li | +1 more

AbstractTrophoblast cell-surface antigen 2 (TROP2)-directed antibody–drug conjugate (ADC) is a promising anticancer agent that has shown remarkable efficacy in several malignancies. However, in lung cancer, two phase 3 trials on TROP2-ADCs in unselected patients with advanced non-small-cell lung cancer (NSCLC) have both failed. Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →